(19)
(11) EP 3 371 225 A2

(12)

(88) Date of publication A3:
29.06.2017

(43) Date of publication:
12.09.2018 Bulletin 2018/37

(21) Application number: 16822517.5

(22) Date of filing: 03.11.2016
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
C07K 16/24(2006.01)
 A61K 39/395(2006.01)
(86) International application number:
PCT/IB2016/001726
(87) International publication number:
WO 2017/077391 (11.05.2017 Gazette 2017/19)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 04.11.2015 US 201562250691 P

(71) Applicant: AstraZeneca AB
151 85 Södertälje (SE)

(72) Inventors:
  • NEWBOLD, Paul
    Gaithersburg, MD 20878 (US)
  • RANADE, Koustubh
    Gaithersburg, MD 20878 (US)

(74) Representative: AstraZeneca 
Milstein Building Granta Park
Cambridge CB21 6GH
Cambridge CB21 6GH (GB)

   


(54) DIPEPTIDYL PEPTIDASE-4 AND PERIOSTIN AS PREDICTORS OF CLINICAL RESPONSE TO EOSINOPHIL-TARGETED THERAPEUTIC AGENTS IN EOSINOPHILIC DISEASES